Search clinical trials for: Ofatumumab

Total 169 results

Novartis Pharmaceuticals

Not yet recruiting

Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis (KATHAROS)

Multiple Sclerosis
Novartis Pharmaceuticals

Not yet recruiting

ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients

Multiple Sclerosis, Relapsing-Remitting
Novartis Pharmaceuticals

Recruiting

A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical Practice (CRONOS-MS)

Relapsing Forms of Multiple Sclerosis

Spain
Novartis Pharmaceuticals

Recruiting

Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France (SEPROS)

Multiple Sclerosis (MS)

France
Novartis Pharmaceuticals

Not yet recruiting

Kesimpta Pregnancy and Infant Safety Study Using Real World Data

Multiple Sclerosis
Novartis Pharmaceuticals

Recruiting

WOE of Anti-CD20 Therapies

Multiple Sclerosis

United States
Aneira Pharma, Inc.
DataPharm Australia, CMAX Clinical Research, Agilex Australia

Not yet recruiting

Phase I Study of Safety and Pharmacokinetics of Topical Solution in Subjects With Androgenetic Alopecia

Androgenetic Alopecia
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer

Breast Cancer

China
Novartis Pharmaceuticals

Recruiting

Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study

Relapsing Multiple Sclerosis

Portugal
Novartis Pharmaceuticals

Recruiting

Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years (KRONOS)

Relapsing Multiple Sclerosis

Austria
Biogen

Recruiting

A Study to Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate

Multiple Sclerosis

United States
Novartis Pharmaceuticals

Recruiting

Kesimpta (Ofatumumab) Pregnancy Registry

Multiple Sclerosis | Pregnancy

United States
Tang-Du Hospital
Henan Provincial People's Hospital

Recruiting

Ofatumumab in AQP4-IgG Seropositive NMOSD

Neuromyelitis Optica Spectrum Disorder

China
Tianjin Medical University General Hospital

Recruiting

Effects of Ofatumumab Treatment on Immune Cells and Meningeal Lymphatic Drainage in Patients With Demyelinating Diseases (OMNISCIENCE)

Multiple Sclerosis | Neuromyelitis Optica Spectrum Disorder | Demyelinating Diseases of the Central Nervous System

China
Novartis Pharmaceuticals

Recruiting

A NIS Evaluating Injectable Treatments in Patients With Relapsing Multiple Sclerosis (AIOLOS)

Relapsing Multiple Sclerosis

Germany
Novartis Pharmaceuticals

Recruiting

Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study (KOSMOS)

Multiple Sclerosis

Switzerland
Novartis Pharmaceuticals

Recruiting

Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf

Relapsing Multiple Sclerosis

United Arab Emirates, Oman
University of Southern California
Novartis Pharmaceuticals

Recruiting

Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment

Relapsing Remitting Multiple Sclerosis

United States
Novartis Pharmaceuticals

Recruiting

A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation (SOSTOS)

Relapsing-Remitting Multiple Sclerosis

Canada, United States
Novartis Pharmaceuticals

Recruiting

Characterizing the Use of Ofatumumab in a Real World Setting (EAFToS)

Relapsing Multiple Sclerosis

Australia
Novartis Pharmaceuticals

Recruiting

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis (NEOS)

Multiple Sclerosis (MS)

United States, Belgium, Spain, Taiwan, Italy, Germany, Canada, Estonia, Mexico, Croatia, Slovakia, Turkey, India, Argentina, France, Australia, Austria, Serbia, Brazil, Guatemala, Latvia, Poland, Portugal, Russian Federation, Romania, United... and more
Novartis Pharmaceuticals

Recruiting

Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS (STHENOS)

Multiple Sclerosis

Germany, Spain, Italy, France, United Kingdom
Brigham and Women's Hospital
Novartis

Recruiting

9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis

Relapsing Multiple Sclerosis

United States
National Institute of Allergy and Infectious Diseases...
PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN); Blood...

Recruiting

Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) (BEAT-MS)

Relapsing Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

United States
Novartis Pharmaceuticals

Recruiting

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS (ALITHIOS)

Relapsing Multiple Sclerosis

United States, Australia, Austria, Belgium, Bulgaria, Canada, Germany, Hungary, Poland, Portugal, Russian Federation, Slovakia, Spain, Denmark, France, Japan, Israel, Taiwan, Turkey, Czechia, Argentina, Estonia, United Kingdom, India, C... and more
Johns Hopkins University
Patient-Centered Outcomes Research Institute; National Multiple Sclerosis Society

Recruiting

Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (TREAT-MS)

Multiple Sclerosis, Relapsing-Remitting

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

Recurrent Adult Lymphoblastic Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia | B Lymphoblastic Lymphoma

United States
Novartis Pharmaceuticals

Terminated

A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

Relapsing Multiple Sclerosis (RMS)

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis; Celgene Corporation

Active, not recruiting

Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Novartis Pharmaceuticals

Completed

A Study to Assess COVID-19 Vaccination Immune Response in Multiple Sclerosis Patients Treated With Ofatumumab

Multiple Sclerosis

United States
Novartis Pharmaceuticals

Active, not recruiting

Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen

Relapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple Sclerosis

Japan
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia

Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent Burkitt Lymphoma | AIDS-Related Burkitt Lymphoma | Atypical Burkitt/Burkitt-Like Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | High Grade B-Cell Lymphoma With MYC, BCL2... and other conditions

United States
Novartis Pharmaceuticals

Active, not recruiting

Study Evaluating Kesimpta® Treatment Effects in Patients With Relapsing Multiple Sclerosis Transitioning From Other Therapies (KAIROS)

Multiple Sclerosis

Germany
GlaxoSmithKline
Iqvia Pty Ltd

Completed

Study to Evaluate the Safety and Clinical Efficacy of Augmentin® Extra Strength-600 in Children With Acute Otitis Media in India

Respiratory Tract Infections | Otitis Media | Infections, Respiratory Tract

India
Novartis Pharmaceuticals

Active, not recruiting

Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls. (AGNOS)

Relapse Remitting Multiple Sclerosis

United States, Puerto Rico
Novartis Pharmaceuticals

Active, not recruiting

A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis (OLIKOS)

Relapsing Multiple Sclerosis

United States, Puerto Rico
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China

Relapsing Multiple Sclerosis

China
National Cancer Institute (NCI)

Active, not recruiting

Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma

Grade 3a Follicular Lymphoma | Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage III Grade 3 Follicular Lymphoma | Ann Arbor Stage...

United States
The Cleveland Clinic
University of Nottingham

Active, not recruiting

Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (DELIVER-MS)

Multiple Sclerosis, Relapsing-Remitting

United States, United Kingdom
Novartis Pharmaceuticals

Active, not recruiting

An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab (ARTIOS)

Relapsing Multiple Sclerosis

United States, Poland, Austria, Belgium, Czechia, Germany, Australia, Switzerland, Lebanon, Argentina, Canada, Slovenia, Bulgaria, Latvia, Russian Federation, Spain, Italy, Turkey, Slovakia, Portugal, Greece, Saudi Arabia, Hungary, No... and more
Novartis Pharmaceuticals

Completed

A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

Relapsing Multiple Sclerosis

United States
Northwestern University
GlaxoSmithKline; National Comprehensive Cancer Network

Active, not recruiting

Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia

Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States, Sweden
Novartis Pharmaceuticals

Completed

A Survey to Evaluate Early Experience From Patient and Care Partner on Injection and Device for KESIMPTA® Indicated for Multiple Sclerosis

Multiple Sclerosis

United States
M.D. Anderson Cancer Center
GlaxoSmithKline

Active, not recruiting

Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy

Lymphoma | Leukemia

United States
Dana-Farber Cancer Institute
GlaxoSmithKline; Gilead Sciences

Active, not recruiting

A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | Acute Lymphoblastic Leukemia in Remission

United States
Roswell Park Cancer Institute
National Comprehensive Cancer Network

Completed

Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Stage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Stage I Mantle Cell Lymphoma | Stage II Contiguous Mantle Cell Lymphoma | Stage II Non-Contiguous Mantle Cell Lymphoma

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
GlaxoSmithKline; Novartis

Completed

Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide

Non-Hodgkin's Lymphoma

United States
Johns Hopkins University
Novartis

Enrolling by invitation

Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab

Multiple Sclerosis | Retinal Degeneration | Visual Acuity | Tomography, Optical Coherence

United States

Search clinical trials for: Ofatumumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations